Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | EIF4A3 | P38919 | 2/20 | 0.43 |
| ▸ | APEX1 | P27695 | 2/20 | 0.40 |
| ▸ | DAO | P14920 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | F7 | P08709 | 1/20 | 0.36 |
| ▸ | F3 | P13726 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4825508 | 0.92 | HPGD (0.46) | HPGDHSD17B10ALDH1A1MEN1USP2 | |
| SCHEMBL4827008 | 0.83 | XDH (0.43) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL4823129 | 0.81 | HPGD (0.49) | HPGDHSD17B10ALDH1A1MEN1USP2 | |
| SCHEMBL6515069 | 0.77 | KDM4E (0.47) | HPGDHSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL4820996 | 0.76 | MTNR1A (0.42) | ALDH1A1KMT2AKDM4EMAPTTDP1 | |
| SCHEMBL4824420 | 0.71 | HPGD (0.48) | HPGDHSD17B10ALDH1A1MEN1USP2 | |
| SCHEMBL7504797 | 0.70 | HPGD (0.50) | HPGDHSD17B10ALDH1A1MEN1USP2 | |
| SCHEMBL8167692 | 0.69 | NFKB1 (0.41) | HPGDHSD17B10ALDH1A1APEX1DAO | |
| SCHEMBL13174693 | 0.67 | GPR35 (0.56) | HPGDHSD17B10ALDH1A1KMT2AEIF4A3 | |
| SCHEMBL10743425 | 0.67 | DAO (0.40) | HPGDHSD17B10ALDH1A1MEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125455-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, Receptor ligands | VERNALIS RESEARCH LIMITED | 2008-05-29 | — | — | US | disclosed |
| US-20080114018-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2008-05-15 | — | — | US | disclosed |
| US-20080090858-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2008-04-17 | — | — | US | disclosed |
| US-7323473-B2 | Administering (S)-1-(2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)-2-propylamine; serotonin receptor antagonists (5HT/5HT2C) for treatment of obesity | VERNALIS RESEARCH LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-7323487-B2 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-7323486-B2 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-20070105889-A1 | Condensed indoline derivatives and their use as 5HT , in particular 5hHT2c, receptor ligands | VERNALIS RESEARCH LIMITED | 2007-05-10 | — | — | US | disclosed |
| US-20070099981-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2007-05-03 | — | — | US | disclosed |
| US-20070099980-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2007-05-03 | — | — | US | disclosed |
| US-7173056-B2 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2007-02-06 | — | — | US | disclosed |
| US-7166632-B2 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-7166613-B2 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-6962939-B1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2005-11-08 | — | — | US | disclosed |
| EP-1202964-B1 | CONDENSED INDOLINE DERIVATIVES AND THEIR USE AS 5HT, IN PARTICULAR 5HT2C, RECEPTOR LIGANDS | VERNALIS RES LTD (GB) | 2005-10-12 | — | — | EP | disclosed |
| US-20050197380-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2005-09-08 | — | — | US | disclosed |
| US-20050192334-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2005-09-01 | — | — | US | disclosed |
| US-20050187282-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands | VERNALIS RESEARCH LIMITED | 2005-08-25 | — | — | US | disclosed |
| EP-1202964-A1 | CONDENSED INDOLINE DERIVATIVES AND THEIR USE AS 5HT, IN PARTICULAR 5HT2C, RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001012602-A1 | CONDENSED INDOLINE DERIVATIVES AND THEIR USE AS 5HT, IN PARTICULAR 5HT2C, RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2001-02-22 | — | — | WO | disclosed |
| US-5633276-A | MELATONIN SYSTEM DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090858-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | HPGD 1808/4885HSD17B10 920/4885ALDH1A1 1748/4885 |
| US-20050197380-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | HPGD 1808/4885HSD17B10 920/4885ALDH1A1 1748/4885 |
| US-20050192334-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | HPGD 1808/4885HSD17B10 920/4885ALDH1A1 1748/4885 |
| US-20080125455-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, Receptor ligands | HTR2C, HTR2A, HTR1A | HPGD 1806/4885HSD17B10 918/4885ALDH1A1 1741/4885 |
| US-20080114018-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | HPGD 1808/4885HSD17B10 920/4885ALDH1A1 1748/4885 |
| US-20050187282-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands | HTR2C, HTR2A, HTR1A | HPGD 1808/4885HSD17B10 920/4885ALDH1A1 1748/4885 |
| US-20070099980-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | HPGD 1808/4885HSD17B10 920/4885ALDH1A1 1748/4885 |
| US-20070105889-A1 | Condensed indoline derivatives and their use as 5HT , in particular 5hHT2c, receptor ligands | HTR2C, HTR2A, HTR5A | HPGD 1544/4885HSD17B10 694/4885ALDH1A1 1407/4885 |
| US-20070099981-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | HPGD 1808/4885HSD17B10 920/4885ALDH1A1 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.